Amgen vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy for 2027?
Amgen vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy for 2027? The Motley Fool
Covered in this story
Analyst targets on Amgen
- Argus Research: at $469 · target $515 by Nov 2027 · Buy via Investing.com India
- Freedom Broker: at $460 · target $470 by Nov 2027 · Hold via Investing.com
- Oppenheimer: at $439 · target $480 by Oct 2027 · Outperform via Investing.com India
“At” is the closing price nearest the day the target was reported, the price we score it from; it is not an earlier target. Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $AMGN yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Amgen →Dalsna Finance is currently tracking 48 stories mentioning Amgen, the earliest published 26 May 2026.
Summary aggregated from The Motley Fool's public RSS feed. The full reporting belongs to The Motley Fool — please read it on their site.